These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. [Progress in the treatment of multiple myeloma]. Wada M; Mizoguchi H Gan To Kagaku Ryoho; 1997 Jul; 24(9):1079-88. PubMed ID: 9239160 [TBL] [Abstract][Full Text] [Related]
45. Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC-HOVON randomized phase III study (06914). Sonneveld P; Suciu S; Weijermans P; Beksac M; Neuwirtova R; Solbu G; Lokhorst H; van der Lelie J; Dohner H; Gerhartz H; Segeren CM; Willemze R; Lowenberg B; ; ; Br J Haematol; 2001 Dec; 115(4):895-902. PubMed ID: 11843823 [TBL] [Abstract][Full Text] [Related]
46. [Recent therapy for refractory myeloma]. Togawa A Rinsho Ketsueki; 1993 Apr; 34(4):450-4. PubMed ID: 8510332 [TBL] [Abstract][Full Text] [Related]
47. VAD-PECC regimen in the treatment of advanced-stage multiple myeloma. Delain M; Linassier C; Petitdidier C; Goupille P; Luthier F; Combe M; Reisenleiter M; Benboubker L; Lamagnère JP; Colombat P J Clin Oncol; 1994 Dec; 12(12):2706-13. PubMed ID: 7989948 [TBL] [Abstract][Full Text] [Related]
48. Low dose thalidomide in patients with relapsed or refractory multiple myeloma. Kees M; Dimou G; Sillaber C; Drach J; Ackermann J; Lechner K; Gisslinger H Leuk Lymphoma; 2003 Nov; 44(11):1943-6. PubMed ID: 14738147 [TBL] [Abstract][Full Text] [Related]
49. Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma. Samson D; Gaminara E; Newland A; Van de Pette J; Kearney J; McCarthy D; Joyner M; Aston L; Mitchell T; Hamon M Lancet; 1989 Oct; 2(8668):882-5. PubMed ID: 2571813 [TBL] [Abstract][Full Text] [Related]
50. Interferon versus interferon plus prednisone remission maintenance therapy for multiple myeloma: a Southwest Oncology Group Study. Salmon SE; Crowley JJ; Balcerzak SP; Roach RW; Taylor SA; Rivkin SE; Samlowski W J Clin Oncol; 1998 Mar; 16(3):890-6. PubMed ID: 9508170 [TBL] [Abstract][Full Text] [Related]
51. A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A Southwest Oncology Group study. Dalton WS; Crowley JJ; Salmon SS; Grogan TM; Laufman LR; Weiss GR; Bonnet JD Cancer; 1995 Feb; 75(3):815-20. PubMed ID: 7828131 [TBL] [Abstract][Full Text] [Related]
52. Intensive chemotherapy with combinations containing anthracyclines for refractory and relapsing multiple myeloma. Finnish Leukaemia Group. Palva IP; Ahrenberg P; Ala Harja K; Almqvist A; Elonen E; Hallman H; Hänninen A; Ilvonen M; Isomaa B; Jouppila J Eur J Haematol; 1990 Feb; 44(2):121-4. PubMed ID: 2180741 [TBL] [Abstract][Full Text] [Related]
53. VAD-based regimens as primary treatment for multiple myeloma. Alexanian R; Barlogie B; Tucker S Am J Hematol; 1990 Feb; 33(2):86-9. PubMed ID: 2301376 [TBL] [Abstract][Full Text] [Related]
54. [VAD regimen for multiple myeloma--the effectiveness as first line therapy]. Fujii Y; Nisimura Y; Tanizawa Y; Azuno Y; Yaga K; Hirosige Y; Kaku K; Kaneko T; Matumoto N Rinsho Ketsueki; 1991 Mar; 32(3):280-2. PubMed ID: 2041172 [TBL] [Abstract][Full Text] [Related]
55. Melphalan-prednisolone and vincristine-doxorubicin-dexamethasone chemotherapy followed by prednisolone/interferon maintenance therapy for multiple myeloma: Japan Clinical Oncology Group Study, JCOG0112. Chou T; Tobinai K; Uike N; Asakawa T; Saito I; Fukuda H; Mizoroki F; Ando K; Iida S; Ueda R; Tsukasaki K; Hotta T; Jpn J Clin Oncol; 2011 Apr; 41(4):586-9. PubMed ID: 21247967 [TBL] [Abstract][Full Text] [Related]
56. [Preliminary report of fludarabine, mitoxantrone and dexamethasone in treating refractory or relapsed multiple myeloma]. Luo SK; Li J; Hong WD; Zhao Y; Tong XZ Ai Zheng; 2005 Dec; 24(12):1518-21. PubMed ID: 16351805 [TBL] [Abstract][Full Text] [Related]
57. [Improved prognosis of generalized AL-amyloidosis in a patient with multiple myeloma treated according to the VAD protocol]. Sarkisova IA; Rameev VV; Kozlovskaia LV; Andreeva NE Ter Arkh; 2003; 75(8):81-2. PubMed ID: 14520860 [No Abstract] [Full Text] [Related]
58. VAD regimen in the treatment of resistant multiple myeloma: slow or fast infusion? Koskela K; Pelliniemi TT; Remes K Leuk Lymphoma; 1993 Jul; 10(4-5):347-51. PubMed ID: 8220133 [TBL] [Abstract][Full Text] [Related]
59. Clinical modulation of multidrug resistance in multiple myeloma: effect of cyclosporine on resistant tumor cells. Sonneveld P; Schoester M; de Leeuw K J Clin Oncol; 1994 Aug; 12(8):1584-91. PubMed ID: 7518859 [TBL] [Abstract][Full Text] [Related]